<sup>131</sup>I治疗甲状腺功能亢进症的影响因素

谭本旭

¹³¹I治疗甲状腺功能亢进症的影响因素

谭本旭

文章导航 > 国际放射医学核医学杂志 > 2003, 27 > 2: (66-69)

引用本文:

Citation:

¹³¹I治疗甲状腺功能亢进症的影响因素

谭本旭

400016 重庆, 重庆医科大学附一院核医学科

作者简介: 谭本旭(1977-),男,硕士研究生,主要从事核医学研究。;

中图分类号: R817.5

The influential factors of ¹³¹I treatment for hyperthyroidism

TAN Ben-xu

Department of Nuclear Medicine, First Affiliated Hospital of Suzhou University, Jangsu Suzhou 215006, China
CLC number: R817.5

摘要: 甲状腺功能亢进症¹³¹I治疗剂量的确定受甲状腺吸碘率、有效半衰期、甲状腺质量、抗甲状腺药物等众多因素影响,¹³¹I治疗的预后情况是这些因素共同作用的结果。
- 甲状腺功能亢进症 /
- ¹³¹I剂量 /
- 甲状腺吸碘率 /
- 有效半衰期 /
- 甲状腺质量 /
- 抗甲状腺药物
Abstract: Many factors such iodine-131 uptake, effective half-life, thyroid volume, and antithyroid drugs affect the iodine-131 dose for every hyperthyroid patient. The outcome of radioiodine therapy in hyperthyroidism is decided by gDI of these factors.
- hyperthyroidism /
- iodine-131 dose /
- iodine-131 uptake /
- effective half-life /
- thyroid volume /
- antithyroid drugs
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Sabri 0, Zimny M, Schreckenberger M, et al. Characterization of therapy failures in radioiodine therapy of Grave's disease without antithyroid agents[J]. Nuklearnedizin, 2001, 40(1):1-6.
[2]	Listewnik MH. Analysis of factors affecting treatment results for toxic goiter with radioactive ¹³¹I[J]. Ann Med Stetin, 2000, 46:109-121.
[3]	Sabri 0, Zimny M, Schreckenberger M. Radioiodine therapy in Grave's disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy[J]. Thyroid, 1999, 9(12):181-188.
[4]	Bockisch A, Jamizky T, Derwanz K. Optimized dose planning of radioiodine therapy of benign thyroidal diseases[J]. J Nucl Med, 1993, 34:1632-1638.
[5]	Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Grave's disease[J]. J Clin Endocrinol Metab, 2002, 87(3):1073-1077.
[6]	Berg GEB, Annika MK, Holmberg EC, et al. Iodine-131 treatment of hyperthyroidism:significance of effective half-life measurements[J]. J Nucl Med, 1996, 37(2):228-232.
[7]	Hancock LD, Tuttle RM, Lmar H, et al. The effect of prpoylth-iouracil on subsequent radioactive iodine therapy in Gravesdisease[J]. Clin Endocrinol(Oxf), 1997, 47(4):425-430.
[8]	Turton DB, Silverman ED, Skakir KM. Timeinterval between the last dose of propylthiouracil and ¹³¹I therapy in-flences cure rates in hyperthyroidism caused by Graves dis-ease[J]. Clin Nucl Med, 1998, 23(12):810-814.
[9]	Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome[J]. J Clin Endocrinol Metab, 2001, 86(8):3611-3617.
[10]	Calegaro JV, Dfreitas Gomes E, Bae SH, et al. One-year follow-up of Grave's disease treatment by our different pro-tocols of radioiodine administration[J]. Panminerva Med, 2000, 42(4):241-245.
[11]	Moka D, Voth E, Schicha H. Effects of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy[J]. Nuclearnedizin, 1997, 36(3):87-92.
[12]	Hermans R, Bowillon R, Laga K, et al. Estimation of thyroid gland volume by spiral computed tomography[J]. Eur Radi-ol, 1997, 7(2):214-216.
[13]	Wesche MF, Tiel van Buul MM, Smits NJ, et al. Ultrasonographic versus scintigraphic measurements of thyroid volume in patients referred ¹³¹I therapy[J]. Nucl Med Com-mun, 1998, 19(4):341-346.
[14]	Lucas KJ. Use of thyroid ultrasound volume in calculating radioactive iodine dose in hyperthyroidism[J]. Thyroid, 2000, 10(2):151-155.
[15]	Nygaard B, Hegedas L, Nielsen KG, et al. Long term effects of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules[J]. Clin Endocrinol(Oxf), 1999, 50(2):197-202.
[16]	Bringmann IM, Van Leeuwen BL, Hennemann G, et al. 0utcome of treatment of hyperthyroidism[J]. J Endocrinol Invest, 1999, 22(4):250-256.
[17]	Yoshimoto M, Iino S, Yoshimura H, et al. A five-year follow-up of two different ¹³¹I treatment methods for Grave's disease and the factors affecting the outcome[J]. Nippon Naibunpi Gakkai Zasshi, 1994, 70(9):995-1006.
[18]	Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Grave's patients with radioiodine:role of thyroid-stimulating and thyrotropin-blocking antibodies and radioiodine-induced thyroid damage[J]. J Clin endocrinol Meteb, 1998, 83(1):40-46.
[19]	Lesie WD, Peterely AE, Dupont JO. Radioiodine treatment outcomes in thyroid glands previously irradiated for grave's hyperthyroidism[J]. J Nucl Med, 1998, 39(4):712-716.
[20]	Trainot AC, Martinot FD, Lazzert M, et al. Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Grave's hyperthyroidism[J]. Phys Med Biol, 2000, 45(1):121-129.
[21]	Estour B, Millot L, Vergely N, et al. Efficacy of low doses of radioiodine in the treatment of autonomous thyroid nodules:importance of dose/area ratio[J]. Thyroid, 1997, 7(3):357-361.

[1]	潘香颖 , 李慧贞 . 甲状腺功能亢进症伴肝功能受损的¹³¹I治疗疗效. 国际放射医学核医学杂志, 2009, 33(3): 179-180. doi: 10.3760/cma.j.issn.1673-4114.2009.03.013
[2]	冯菲 , 赵德善 . ¹³¹I治疗青少年儿童甲状腺功能亢进症. 国际放射医学核医学杂志, 2009, 33(3): 171-174,183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.011
[3]	王长修 . 甲状腺功能亢进症患者再次¹³¹I治疗的给药剂量对比研究. 国际放射医学核医学杂志, 2009, 33(3): 182-183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.016
[4]	江英 , 朱玉泉 , 胡凤琼 , 郑春晓 , 王钦 , 易于颦 . 甲亢患者¹³¹I治疗后周围剂量当量率的变化及其影响因素的研究. 国际放射医学核医学杂志, 2022, 46(5): 284-289. doi: 10.3760/cma.j.cn121381-202105010-00183
[5]	郭坤 , 高蕊 , 于燕 , 刘岩 , 杨爱民 . 表皮生长因子受体基因表达与甲状腺功能亢进症¹³¹I治疗预后的关系. 国际放射医学核医学杂志, 2015, 39(1): 4-8. doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
[6]	陈丹云 , 静进 . 甲状腺功能亢进症治疗方法的选择. 国际放射医学核医学杂志, 2007, 31(4): 228-231.
[7]	孙琦婷 , 赵德善 . Graves病甲状腺功能亢进症与血糖代谢. 国际放射医学核医学杂志, 2010, 34(3): 143-147. doi: 10.3760/cma.j.issn.1673-4114.2010.03.004
[8]	罗章伟 , 李天资 , 黄俊玲 , 陆进 , 方文珠 . 6h内摄¹³¹I率快速推断甲状腺功能亢进症患者24h摄¹³¹I率的应用价值. 国际放射医学核医学杂志, 2009, 33(5): 300-301. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.014
[9]	苏莉 , 陈璟 , 赵明 . ¹³¹I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较. 国际放射医学核医学杂志, 2007, 31(6): 366-369.
[10]	汤建林 , 李玉莹 , 高柳艳 , 唐秀萍 , 胡红永 . 甲状腺功能亢进症治疗方法的比较和选择. 国际放射医学核医学杂志, 2009, 33(3): 175-178. doi: 10.3760/cma.j.issn.1673-4114.2009.03.012